JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)
Favorable safety and tolerability profile, with rapid onset of clinical activity and therapeutic effects observed in patients with LAD
June 3, 2026